Skip to main content

Table 3 Changes of the risk of hip fracture

From: Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients

FRAXTreatment 1 (n = 18)p*Treatment 2 (n = 20)p*Control (n = 18)p*
Before treatment5.76 ± 1.455.86 ± 1.595.83 ± 1.74
6 months5.08 ± 2.170.0475.98 ± 2.730.0975.65 ± 1.670.145
12 months4.34 ± 1.780.0355.44 ± 1.890.0725.64 ± 2.090.139
  1. *p values indicate the comparison with that before treatment within the same group; indicates p < 0.05 for the comparison between two groups at the same time point on their difference over the treatment